Impact of delayed appointments on treatment outcomes in neovascular macular degeneration
Acta Ophthalmologica · 2026-12 · 104 (8)
DOI: 10.1111/aos.70169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 18.05.2026. Verfasst von Petri Purola und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Visual Acuity, Bevacizumab, Wet Macular Degeneration, Appointments and Schedules. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tampere University Hospital Support Foundation, The Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital, The Finnish Eye Foundation.
Abstract (Originalsprache)
Purpose
To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Methods
This single‐centre retrospective study included a cohort of 3831 treatment‐naïve nAMD patients who were treated with bevacizumab monotherapy using a pro re nata protocol between 2008 and 2023, comprising a total of 79 545 visits. Visual acuity (VA) was measured at the time of diagnosis and during follow‐up visits and was converted into Early Treatment Diabetic Retinopathy Study letters. One eye per patient was included in the analysis. Delayed visits were categorised as >6 weeks and ≤8 weeks, >8 weeks and ≤ 10 weeks and >10 weeks.
Results
After an initial stabilisation in VA during the first treatment year, VA started to decline. The proportion of visits delayed >6 weeks varied between 24% and 36% per treatment year, with delays being more common during the early years of the study when the new therapies were introduced. In general, the decline in VA was more severe with a higher number and longer duration of delayed visits.
Conclusions
Delays in anti‐VEGF injections are common and strongly associated with vision loss. Therefore, it is important to improve patient awareness and compliance. Use of new longer‐acting therapies may support this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Finnish Register of Visual Impairment, Finnish Federation of the Visually Impaired, Helsinki, Finland.
- Tays Eye Center, Tampere University Hospital, Tampere, Finland.
ORCID-Profile: Petri Purola, Pekko Hujanen
Förderung
- Tampere University Hospital Support Foundation
- The Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital
- The Finnish Eye Foundation
- State Funding for University-Level Health Research, Tampere University Hospital, Wellbeing Services County of Pirkanmaa
- Suomen Kulttuurirahasto
- Sokeain Ystävät
- Finnish Federation of the Visually Impaired
- Silmäsäätiö
Zitieren
APA
Purola, P., Hujanen, P., Uusitalo, H., & Uusitalo-Järvinen, H. (2026). Impact of delayed appointments on treatment outcomes in neovascular macular degeneration. Acta Ophthalmologica, 104(8). https://doi.org/10.1111/aos.70169
Vancouver
Purola P, Hujanen P, Uusitalo H, Uusitalo-Järvinen H. Impact of delayed appointments on treatment outcomes in neovascular macular degeneration. Acta Ophthalmologica. 2026;104(8). doi:10.1111/aos.70169
BibTeX
@article{Purola2026,
author = {Purola, Petri and Hujanen, Pekko and Uusitalo, Hannu and Uusitalo-Järvinen, Hannele},
title = {Impact of delayed appointments on treatment outcomes in neovascular macular degeneration},
journal = {Acta Ophthalmologica},
year = {2026},
volume = {104},
number = {8},
doi = {10.1111/aos.70169}
}
EUVIMED